One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology

OBJECTIVE: The aim was to study the effect of non-mandatory transitioning from etanercept originator to etanercept biosimilar on retention rates in a setting promoting shared decision-making. METHODS: In 2016, all patients treated with etanercept originator and stable disease at the Rheumatology dep...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Rheumatol Adv Pract
Päätekijät: Müskens, Wieland D, Rongen-van Dartel, Sanne A A, Teerenstra, Steven, Adang, Eddy M M, van Riel, Piet L C M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7519774/
https://ncbi.nlm.nih.gov/pubmed/33005860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rap/rkaa042
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia